Clinical management of patients with insomnia. The role of zopiclone

PharmacoEconomics

Volumn 10, Issue SUPPL. 1, 1996, Pages 29-38

  Hajak, Göran ^a   Rodenbeck, Andrea ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ZOPICLONE;

CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INSOMNIA; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0029736845     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600101-00006     Document Type: Conference Paper

References (95)

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985; 42: 225-32
2. Lugaresi E, Zucconi M, Bixler EO. Epidemiology of sleep disorders. Psychiatric Ann 1987; 17: 446-53
3. Lack L, Miller W, Turner D. A survey of sleeping difficulties in an Australian population. Community Health Stud 1988; 12: 200-7
4. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262: 1479-84
5. Simen S, Hajak G, Schlaf G, et al. Chronifizierung von Schlafbeschwerden - Ergebnisse einer Representativumfrage in Westdeutschland. Nervenarzt 1995; 66: 686-95
6. Becker PM, Jamieson AO, Brown WD. Insomnia. Use of a 'decision tree' to assess and treat. Postgrad Med 1993; 93: 66-70
7. Schramm E, Hohagen F, Grasshoff U, et al. Test-retest reliability and validity of a structured interview for sleep disorders according to DSM-III-R. Am J Psychiatry 1993; 150: 867-72
8. Borbély AA, Mattmann P, Loepfe M, et al. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985; 4: 189-94
9. Broughton RJ. Phasic and dynamic aspects of sleep: a symposium review and synthesis. In: Terzano MG, Halasz P. Declerck AC, editors. Phasic events and dynamic organization of sleep. New York: Raven, 1991: 185-206
10. American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual. Lawrence: Allen, 1990
11. Lacks P. Behavioral treatment for persistent insomnia. New York: Pergamon, 1987
12. Espie CA. The psychological treatment of insomnia. New York: Wiley, 1991
13. Hauri P, editor. Case studies in insomnia. New York: Plenum, 1991
14. Morin CM. Psychological management of insomnia. New York: Guilford, 1993
15. Goa KL, Heel RC. Zopiclone. A review of its pharmacody namic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32: 48-65
16. Musch B, Maillard F. Zopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 147-58
17. Gaillard JM. Benzodiazepine receptor agonists: a comparative portrait. Kalamazoo: Upjohn, 1992
18. Wadworth AN, McTavish D, Zopiclone. A review of its pharmacological and therapeutic efficacy as an hypnotic. Drugs Aging 1993; 3: 441-59
19. Kerr JS, Dawe RA, Parkin C, et al. Zopiclone in elderly patients: efficacy and safely. Hum Psychopharmacol 1995; 10: 221-9
20. Coleman RM Roffwarg HP, Kennedy SJ, et al. Sleep-wake disorders based on a polysomnographic diagnosis. JAMA 1982; 247: 997-1003
21. Coleman RM. Diagnosis, treatment and follow-up of about 8000 sleep/wake disorders patients. In: Guilleminault C, Lugaresi E, editors. Sleep/wake disorders. New York: Raven, 1983: 87-98
22. Jacobs EA, Reynolds II CF, Kupfer DJ, et al. The role of polysomnography in the differential diagnosis of chronic insomnia. Ann J Psychiatry 1988; 154: 346-9
23. Gillin JC, Byerley WF. Drug-therapy: the diagnosis and management of insomnia. N Engl J Med 1990; 322: 239-48
24. Jamieson AO, Becker PM. Management of the 10 most common sleep disorders. Am Family Physician 1992; 45: 1262-8
25. Hajak G, Rüther E. Insomnie. Berlin: Springer, 1995
26. Hajak G, Müller-Popkes K, Riemann D, et al. Psychological, psychotherapeutical and other forms of nonpharmacological treatment of insomnia. Statement from the Expert Group on Insomnia of the German Sleep Society. Fortschr Neurol Psychiatr. In press
27. The World Psychiatric Association, Task Force on Sedative Hypnotics (1993). Eur Psychiatry 1993; 8: 45-9
28. Brun JP. Zopiclone, a cyclopyrrolone hypnotic: review of properties. Pharmacol Biochem Behav 1988; 29: 831-2
29. Inman W, Kubota K, Pearce G, et al. PEM report numher 10. Zopiclone. Pharmacoepidemiol Drug Saf 1993; 2: 499-521
30. Allain H, Delahaye C, Lecoz F, et al. Post-marketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991; 14: 408-13
31. Hindmarch I, editor. Zopiclone (monograph). Manchester: Adis International, 1990
32. Borbély AA, Akerstedt T, Benoit O, et al. Hypnotics and sleep physiology: a consensus report. Eur Arch Psychiatry Clin Neurosci 1991; 241: 13-21
33. Kuitunen T, Mattila MJ, Seppala T, et al. Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 1990; 30: 453-61
34. Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992; 70: 286-9
35. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Pharmacol 1990; 5 Suppl. 2: 137-45
36. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology 1992; 108: 248-55
37. Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry 1992; 53 Suppl.: 10-7
38. Dement WC, Seidel W, Carskadon MA. Issues in the diagnosis and treatment of insomnia. Psychopharmacology 1984; Suppl. 1: 11-43
39. Kupfer D. Interaction of EEG sleep, antidepressants and affective disease. J Clin Psychiatry 1982; 43: 30-5
40. Scharf MB, Hirschowitz J, Zemlan FP, et al. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. J Clin Psychiatry 1986; 47: 587-91
41. Wiegand M, Berger M, Zulley J, et al. The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry 1986; 19: 198-9
42. Hohagen F, Fritsch Monero R, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994; 244: 65-72
43. Rodenbeck A, Hajak G, Herrendorf G, et al. Schlafpolygraphische und neuroendokrine Aspekte zur Wirkung trizyklischer Antidepressiva in der Behandlung von Insomniepatienten. Wien Med Wochenschr 1994; Suppl. 1: 62-73
44. Finke J. Neuroleptika bei Schlafstörungen. Therapiewoche 1976; 26: 3818-26
45. Malsch U. Behandlung von Schlafstörungen bei älteren Patienten. Therapiewoche 1987; 37: 2484-7
46. Shapiro S, Slone D, Lewis GP, et al. Clinical effects of hypnotics. JAMA 1969; 209: 2016-20
47. Hartman E, Cravens J. The effects of long term administration of psychotropic drugs on human sleep. V. The effects of chloral hydrate. Psychopharmacologica 1973; 33: 219-32
48. Piccione P, Zorick F, Lutz T, et al. The efficacy of triazolam and chloralhydrate in geriatric insomniacs. J Int Med Res 1980; 8: 361-7
49. Groβkopf E. Behandlung von Schlafstörungen. Objektivierung der Wirkung und Verträglichkeit von Chloralhydrat. Therapiewoche 1988; 38: 584-6
50. Jovanovic UJ. Die Einwirkungen von Chloralhydrat auf Schlafstörungen bei psychosomatischen Patienten. Nervenheilkunde 1992; 11: 350-8
51. Rickels K, Morris RJ, Newman H, et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983; 23: 235-42
52. Rickels K, Ginsberg J, Morris RJ. Doxylaminc succinate in insomniac family practice patients: a double-blind study. Curr Ther Res 1984; 35: 532-40
53. Spiegel R, Allen SR. Die Wirkung eines nicht rezeptpflichtigen Schlafmittels auf das Schlafpolygramm gesunder Probanden. Schweiz Rundsch Med Prax 1984; 73: 163-73
54. 2 antagonists. Neuropharmacology 1985; 24: 245-50
55. Balderer E, Borbély AA. Effect of valerian on human sleep. Psychopharmacology 1985; 87: 406-9
56. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989; 32: 1065-6
57. Schulz H, Stolz C, Müller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 1994; 27: 147-51
58. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV. Washington DC: American Psychiatric Association, 1994
59. World Health Organization. Tenth revision of the International Classification of Diseases, chapter V (F): mental and behavioural disorders (including disorders of the psychological development). Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1991
60. Parsons M. Fits and other causes of loss of consciousness while driving. Q J Med 1986; 58: 295-303
61. Kripke DF, Ancoli-Israel S, Fell RL, et al. Health risk of insomnia. In: Peter JH, Penzel T, Podszus T, et al., editors. Sleep and health risk. Berlin: Springer, 1991: 547-54
62. Klink ME, Quan SF, Kaltenborn WT, et al. Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia. Arch Intern Med 1992; 152: 1634-7
63. Martikainen K, Hasan J, Urponen H, et al. Daytime sleepiness: a risk factor in community life. Acta Neurol Scand 1992; 86: 337-41
64. Partinen M, editor. Daytime well-being of insomniacs, toward a quantitative assessment; the contribution of zopiclone. JAMA SEA 1993; Suppl. 9
65. Billiard M, Guelfi JD, editors. Zopiclone: from clinical practice to quality of life. Eur Psychiatry 1995; 10 Suppl. 3:
66. Hajak G, Clarenbach P, Fischer W, et al. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994; 9: 251-61
67. Hajak G, Clarenhach P, Fischer W, et al. Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatry 1995; Suppl. 3: 173-9
68. Morin CM, Gramling SE. Sleep patterns and aging: comparison of older adults with and without insomnia complaints. Psychol Aging 1989; 4: 290-4
69. Gislason T, Reynisdottir H, Kristbjarnarson H, et al. Sleep habits and sleep disturbances among the elderly - an epidemiological survey. J Intern Med 1993; 234 (1): 31-9
70. Hauri P, Fisher J. Persistent psychophysiologic (learned) insomnia. Sleep 1986; 9 (1): 38-53
71. Espie CA, Lindsay WR, Brooks ON, et al. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behav Res Ther 1989; 27: 79-88
72. Lacks P, Powlishta K. Improvement following behavioral treatment for insomnia: clinical significance, long-term maintenance, and predictors of outcome. Behav Ther 1989; 20: 117-34
73. Morin CM, Culbert JP, Kowatch RA, et al. Efficacy of cognitive-behavioral treatments for insomnia: a meta-analytic review. Sleep Res 1989; 18: 272
74. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994; 151 (8): 1172-80
75. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995; 63 (1): 79-89
76. Clarenbach P, Steinberg R, Weess HG, et al. Recommendations for the diagnostic and therapeutic handling of insomnia. German Sleep Society. Nervenarzt 1995; 66: 723-9
77. Morin CM, Kwentus JA. Behavioral and pharmacological treatments for insomnia. Ann Behav Med 1988; 10: 91-100
78. Milby JB, Williams V, Hall JN, et al. Effectiveness of combined triazolam-behavioral therapy for primary insomnia. Am J Psychiatry 1993; 150: 1259-60
79. Chiffoleau A, Baudot S, Larousse C, et al. Zopiclone: what does happen after discontinuation of long term treatment? Paper presented at the 13th EME Journées Francaises de Pharmacovigilance: Nice, 1991
80. Morgan K. Hypnotics in the elderly: what cause for concern? Drugs 1990; 10:688-96
81. Roehrs T, Vogel G, Roth R. Rebound insomnia: its determinants and significance. Am J Med 1990; 88 Suppl. 3A: 395-425
82. Psychological ADRs with zopiclone. Pharm J 1990: 210
83. Thakore J, Dinan TG. Physical dependence following zopiclone usage: a case report. Hum Psychopharmacol 1992; 7: 143-5
84. Sullivan G, McBride AJ, Clee WB. Zopiclone abuse in South Wales: three case reports. Hum Psychopharmacol 1995; 10: 351-2
85. Aranko K, Henriksson M, Hublin C, et al. Misuse of zopiclone and convulsions during withdrawal. Pharmacopsychiatry 1991; 24: 138-40
86. Cowen PJ, Nutt DJ. Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet 1982; 2: 360-2
87. Tyrer P. Zopiclone: another carriage on the tranquilliser train. Lancet 1990; 335: 507-8
88. Office of Medical Applications of Research. National Institutes of Health. Drugs and insomnia. The use of medication to promote sleep. JAMA 1984; 251: 2410-4
89. American Psychiatric Association. Benzodiazepine dependence, toxicity and abuse. A Task Force report. Washington DC: American Psychiatric Association, 1990
90. National Institutes of Health Consensus Development Conference consensus statement. The treatment of sleep disorders of older people. Bethesda: Office of Medical Applications, 1990
91. Rüther E, Epidemiologie, Pathophysiologie, Diagnostik und Therapie von Schlafstörungen. Ergebnisse einer Consensus-Konferenz der Arbeitsgemeinschaft Klinischer Schlafzentren (AKS) und der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Munch Med Wochenschr 1992; 134: 460-6
92. Commission of the European Communities. Ad hoc group on short acting hypnotic. Summary report to the Commmittee for the Proprietary Medicinal Products (CPMP). Brussels, 1993
93. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Impact of neuropharmacology in the 1990s - treatment strategies for anxiety disorders and insomnia. Eur Neuropsychopharmacol 1992; 2: 167-9
94. Hajak G, Hajak P, Rüther E. Therapie von Ein- und Durchschlafstörungen - Moderne Konzepte für die Anwendung von Schlafmitteln. TW Neurologie Psychiatrie 1993; 7: 561-74
95. Borbély AA. Benzodiazepinhypnotika: Wirkungen und Nachwirkungen von Einzeldosen. In: Hippius H, Engel RR, Laakmann G, editors. Benzodiazepine. Rückblick und Ausblick. Berlin: Springer, 1986: 96-100